The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases
Abstract
Purpose: This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd). Patients and Methods: Patients were randomly assigned to 30 Gy of WBRT ± 5 mg/kg/d MGd. Survival and time to neurologic progression determined by a blinded events review committee (ERC) were coprimary end points. Standardized investigator neurologic assessment and neurocognitive testing were evaluated. Results: Four hundred one (251 non–small-cell lung cancer) patients were enrolled. There was no significant difference by treatment arm in survival (median, 5.2 months for MGd v 4.9 months for WBRT; P = .48) or time to neurologic progression (median, 9.5 months for MGd v 8.3 months for WBRT; P = .95). Treatment with MGd improved time to neurologic progression in patients with lung cancer (median, not reached for MGd v 7.4 months for WBRT; P = .048, unadjusted). By investigator, MGd improved time to neurologic progression in all patients (median, 4.3 months for MGd v 3.8 months for WBRT; P = .018) and in lung cancer patients (median, 5.5 months for MGd v 3.7 months for WBRT; P = .025). MGd improved neurocognitive function in lung cancer patients. Conclusion: The overall results did not demonstrate significant differences by treatment arm for survival and ERC time to neurologic progression. Investigator neurologic assessments demonstrated an MGd treatment benefit in all patients. In lung cancer patients, ERC- and investigator-determined time to neurologic progression demonstrated an MGd treatment benefit. MGd may improve time to neurologic and neurocognitive progression in lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Borgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., & Hendrickson, F. R. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90195-9 · Cited by 953
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., Whedon, M. B., Bivens, S., Mitchell, T., Greenberg, E. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.485 · Cited by 736
Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
Gaspar, L. E., Scott, C., Murray, K., & Curran, W. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00547-2 · Cited by 529
Self-citationKurtz, J. M., Gelber, R., Brady, L. W., Carella, R. J., & Cooper, J. S. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90005-5 · Cited by 331
Murray, K. J., Scott, C., Greenberg, H. M., Emami, B., Seider, M., Vora, N. L., Olson, C., Whitton, A., Movsas, B., & Curran, W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00341-6 · Cited by 314
Self-citationProperties of the urn randomization in clinical trials
Wei, L. J., & Lachin, J. M. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90048-7 · Cited by 308
Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma
Meyers, C. A., Hess, K. R., Yung, W. K. A., & Levin, V. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.646 · Cited by 271
T.Komarnicky, L., Phillips, T. L., Martz, K., Asbell, S., Isaacson, S., & Urtasun, R. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90137-s · Cited by 237
Nieder, C., Nestle, U., Motaref, B., Walter, K., Niewald, M., & Schnabel, K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00416-2 · Cited by 166
Mehta, M. P., Shapiro, W. R., Glantz, M., Patchell, R. A., Weitzner, M. A., Meyers, C. A., Schultz, C. J., Roa, W., Leibenhaut, M. H., Ford, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.500 · Cited by 148
Self-citationChemotherapy response criteria in malignant glioma
Grant, R., Liang, B. C., Slattery, J. M. A., Greenberg, H. S., & Junck, L. (1997) · Neurology · doi:10.1212/wnl.48.5.1336 · Cited by 67
Radiotherapy for brain metastases: defining palliative response
Bezjak, A., Adam, J., Panzarella, T., Levin, W., Barton, R., Kirkbride, P., McLean, M., Mason, W. P., Wong, C. S., & Laperrière, N. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00426-1 · Cited by 53
Self-citation
Cited by
Gondi, V., Pugh, S. L., Tome, W. A., Caine, C., Corn, B., Kanner, A., Rowley, H., Kundapur, V., DeNittis, A., Greenspoon, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2909 · Cited by 1,148
Self-citationAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., Moore, B., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 711
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Meyers, C. A., Smith, J. A., Bezjak, A., Mehta, M. P., Liebmann, J., Illidge, T., Kunkler, I., Caudrelier, J.-M., Eisenberg, P. D., Meerwaldt, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.128 · Cited by 585
Self-citation
Metadata
- Authors
- Mehta, M. P., Rodrigus, P., Terhaard, C. H. J., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., Schultz, C., Timmerman, R., Curran, W., Smith, J., Phan, S.-C., Miller, R. A., & Renschler, M. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-01
- Volume
- 21
- Issue
- 13
- Pages
- 2529-2536
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113465576
- Cited by
- 463
- References
- 15
- FWCI
- 19.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.